Khanya Eggs Business Plan — Executive Summary
A staged commercial layer enterprise: R950,000 to start, 30,000 birds by Year 5, R18.46m revenue and a 27.4% EBITDA margin at maturity.
Executive Summary
Jump to section
- Overview & contents
- i. Important Notice
- 1. Executive Summary
- 2. The South African Egg Market
- 3. Avian Influenza: The Risk That Defines This Business
- 4. SWOT and Competitive Position
- 5. The Five-Stage Roadmap
- 6. The Funding Ladder
- 7. Flock Performance
- 8. Feed Strategy
- 9. Point-of-Lay Pullet Sourcing
- 10. Biosecurity
- 11. Route to Market and Pricing
- 12. Operations and People
- 13. Regulation and Compliance
- 14. Unit Economics
- 15. Capital Expenditure
- 16. Financial Projections
- 17. Break-Even
- 18. Sensitivity and the Grant Question
- 19. Risk Management
- 20. Implementation Roadmap
- 21. Returns
- 22. Key Performance Indicators
- 23. Key Assumptions
- 24. Conclusion
- A. Appendix A: Consolidated Financial Summary
- B. Appendix B: Stage Capital Schedules
- C. Appendix C: Debt Schedules
- D. Appendix D: Risk Register
- E. Appendix E: Funding Application Checklist
- F. Appendix F: Glossary
- 1.1 The proposition
- 1.2 The three things that matter
- 1.3 Headline numbers
- 1.4 Returns
1.1 The proposition
Khanya Eggs is a start-up layer enterprise producing table eggs for the South African market. It begins with 500 laying hens and grows to 30 000 by Year 5 through five discrete, separately funded stages.
By Year 5 the farm sells 6.18 million eggs a year, about 206 127 trays, generating revenue of R18.46 million and EBITDA of R5.06 million at a margin of 27.4 per cent. Total capital deployed across the five years is R13.53 million, of which the founder contributes R450 000 in cash.
|
R18.46m Year 5 revenue |
R5.06m Year 5 EBITDA |
R450 000 Founder cash required |
R3.65m Grant funding targeted |
1.2 The three things that matter
- Below roughly 7 400 hens in lay, this is not a business. Gross margin per hen is R372.70 a year at maturity and the fixed cost base at Year 5 scale is R2.76 million. Measured against its own contemporaneous cost base the farm crosses break-even during Year 3, when 3 900 average hens in lay exceed the 3 205 the Year 3 cost base requires. Stages 1 and 2 are a funded apprenticeship that builds the track record needed to access the capital for Stages 4 and 5.
- Avian influenza is the risk that can end the business overnight, and South Africa pays no compensation. The 2023 outbreak cost the industry around R10.5 billion and more than 30 per cent of its long-living birds. A vaccination framework was only formalised in June 2026. Section 3 sets out what this means for a farm whose entire asset is a live flock.
- The direct sales channel is what makes the margin work. A small producer selling at the farm gate and into local trade earns materially more per egg than one selling only into wholesale. As volume grows the mix inevitably shifts toward wholesale, and the plan models the blended price falling in real terms as a result.
1.3 Headline numbers
|
R’000 unless stated |
Year 1 |
Year 2 |
Year 3 |
Year 4 |
Year 5 |
|---|---|---|---|---|---|
|
Birds at year end |
500 |
2 000 |
6 000 |
15 000 |
30 000 |
|
Average hens in lay |
330 |
1 300 |
3 900 |
9 800 |
21 000 |
|
Eggs sold, thousands |
87 |
358 |
1 106 |
2 845 |
6 184 |
|
Blended price per egg, R |
2.77 |
2.78 |
2.75 |
2.75 |
2.81 |
|
Revenue |
256 |
1 055 |
3 233 |
8 316 |
18 461 |
|
Direct costs |
(176) |
(683) |
(2 038) |
(5 067) |
(10 635) |
|
Gross margin |
80 |
372 |
1 195 |
3 249 |
7 827 |
|
Fixed costs |
(288) |
(514) |
(982) |
(1 729) |
(2 762) |
|
EBITDA |
(208) |
(142) |
213 |
1 520 |
5 065 |
|
EBITDA margin |
-81.2% |
-13.5% |
6.6% |
18.3% |
27.4% |
|
Profit after tax |
(283) |
(364) |
(265) |
557 |
2 555 |
|
Capital deployed |
650 |
853 |
1 760 |
4 100 |
6 170 |
|
Closing cash |
70 |
226 |
628 |
1 841 |
3 637 |
1.4 Returns
|
Measure |
Value |
Comment |
|---|---|---|
|
Return on capital deployed, Year 5 |
37.4% |
Year 5 EBITDA of R5.07m against R13.53m of cumulative capital |
|
Return on capital employed, Year 5 |
26.3% |
Year 5 EBIT of R3.96m against equity and debt of R15.01m |
|
Payback on capital |
2.7 years |
At the Year 5 EBITDA run rate |
|
Project IRR to Year 5 |
79.3% |
At a terminal value of 5.0x Year 5 EBITDA; a range is set out in Section 21 |
|
Founder money multiple |
45.0x |
On R450 000 of founder cash; grants are non-repayable and non-dilutive |
|
EBITDA cover of debt service, Year 5 |
5.42x |
Against the Stage 5 gate of 1.5 times |
|
Same, with no grant funding at all |
3.23x |
Every rand of grant replaced by an 11% loan; see Section 18.3 |